Traws Pharma, Inc.
TRAW
$0.83
-$0.01-0.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -12.82% | 33.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.73% | 81.70% | |||
| Operating Income | 5.73% | -81.70% | |||
| Income Before Tax | 4.51% | -87.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 4.51% | -87.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.51% | -87.86% | |||
| EBIT | 5.73% | -81.70% | |||
| EBITDA | 5.76% | -81.29% | |||
| EPS Basic | 7.26% | -67.63% | |||
| Normalized Basic EPS | 16.03% | -77.03% | |||
| EPS Diluted | 7.26% | -67.63% | |||
| Normalized Diluted EPS | 16.03% | -77.03% | |||
| Average Basic Shares Outstanding | 13.70% | 6.11% | |||
| Average Diluted Shares Outstanding | 13.70% | 6.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||